A New Prognostic Indicator for Biliary Tract Cancers: The ABIC Score
Current Oncology · 2025
DOI: 10.3390/curroncol32040200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Doğan Bayram und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara City Hospital, 06800 Ankara, Turkey. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Bilirubin, Creatinine. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Biliary tract cancers (BTC) comprise a heterogeneous group of malignancies, including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The main determinants of prognosis in BTC are the stage of the disease and the eligibility for curative treatment. Additionally, liver functional capacity is also one of the factors influencing survival in biliary tract cancers. The age–bilirubin–INR–creatinine (ABIC) score has been previously shown to predict prognosis in hepatic diseases. The aim of our study is to demonstrate the relationship between the ABIC score and prognosis in BTC. Materials and Methods: In this study, a retrospective analysis was performed on 41 patients with non-metastatic BTC and 73 patients with metastatic BTC who were followed up in our clinic between 2003 and 2025. All patients were ≥18 years old at the time of diagnosis, and BTC was pathologically confirmed. The ABIC score was calculated separately for each group. A threshold value for the ABIC score was determined using Receiver Operating Characteristic (ROC) analysis, and based on this threshold, patients were divided into low and high ABIC score groups. Both the relationship between the ABIC score and prognosis and the other factors affecting prognosis were investigated.
Results
In the non-metastatic BTC group, the cutoff value for the ABIC score was 6.89. The median survival time of patients with a high ABIC score was significantly shorter. In the metastatic BTC group, the cutoff value for the ABIC score was 7.41. Similarly, in this group, patients with a high ABIC score had a significantly shorter median survival time. Additionally, in the non-metastatic BTC group, tumor localization and stage were prognostic factors affecting survival, while in the metastatic BTC group, CEA and first-line chemotherapy were the prognostic factors influencing overall survival.
Conclusions
We demonstrate that the ABIC score is a prognostic factor determining median survival in both non-metastatic and metastatic BTC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Ankara City Hospital, 06800 Ankara, Turkey.
- Department of Medical Oncology, University of Health Sciences, Ankara City Hospital, 06800 Ankara, Turkey.
- Medical Oncology, Afyonkarahisar State Hospital, 03100 Afyonkarahisar, Turkey.
- Diyarbakır Gazi Yaşargil Education Research Hospital, 21010 Diyarbakır, Turkey.
ORCID-Profile: Doğan Bayram, Öznur Bal, Serhat Sekmek, Perihan Perkin, Fahriye Tuğba Köş, Doğan Uncu
Zitieren
APA
Bayram, D., Bal, Ö., Karaman, K., Bardakçı, M., Demirtaş Esmer, D., Seven, İ., Sekmek, S., Perkin, P., Köş, F. T., Algın, E., & Uncu, D. (2025). A New Prognostic Indicator for Biliary Tract Cancers: The ABIC Score. Current Oncology. https://doi.org/10.3390/curroncol32040200
Vancouver
Bayram D, Bal Ö, Karaman K, Bardakçı M, Demirtaş Esmer D, Seven İ, et al. A New Prognostic Indicator for Biliary Tract Cancers: The ABIC Score. Current Oncology. 2025. doi:10.3390/curroncol32040200
BibTeX
@article{Bayram2025,
author = {Bayram, Doğan and Bal, Öznur and Karaman, Kemal and Bardakçı, Murat and Demirtaş Esmer, Derya and Seven, İsmet and Sekmek, Serhat and Perkin, Perihan and Köş, Fahriye Tuğba and Algın, Efnan and Uncu, Doğan},
title = {A New Prognostic Indicator for Biliary Tract Cancers: The ABIC Score},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32040200}
}
EUVIMED